Sarepta Therapeutics Inc (SRPT)

32.66
0.46 1.43
NASDAQ : Health Care
Prev Close 32.20
Open 32.50
Day Low/High 31.81 / 33.38
52 Wk Low/High 8.00 / 41.97
Volume 1.74M
Avg Volume 4.49M
Exchange NASDAQ
Shares Outstanding 54.59M
Market Cap 1.87B
EPS -5.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

PTC Therapeutics Duchenne Drug Wins Extended European Approval

PTC Therapeutics Duchenne Drug Wins Extended European Approval

The news that Translarna will remain on the European market for at least five more years sent PTC Therapeutics shares soaring.

Sarepta Therapeutics To Present Company Overview At The Credit Suisse 25th Annual Healthcare Conference

Sarepta Therapeutics To Present Company Overview At The Credit Suisse 25th Annual Healthcare Conference

Sarepta Therapeutics (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, announced today that it is scheduled to present at the Credit Suisse 25 th Annual Healthcare Conference...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on October 31, 2016, that were previously approved by the Compensation Committee of...

Sarepta Therapeutics Announces Third Quarter 2016 Financial Results And Recent Corporate Developments

Sarepta Therapeutics Announces Third Quarter 2016 Financial Results And Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today reported financial results for the three and nine months ended September 30, 2016.

In Case You Missed It: Wednesday, Oct. 26

In Case You Missed It: Wednesday, Oct. 26

Microsoft released upgrades and products Wednesday including "Surface Studio" for artists. Bill Gates, Microsoft's Co-Founder, appears below with an early computer running the Paint program, the first of its kind.

Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta

Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta

More about Vertex' Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.

'Mad Money' Lightning Round: Yum! Brands Split is a 'Great Idea'

'Mad Money' Lightning Round: Yum! Brands Split is a 'Great Idea'

Jim Cramer likes YUM; says STZ is more appetizing than MNST

Jim Cramer's 'Mad Money' Recap: Don't Surrender to the Index Funds

Jim Cramer's 'Mad Money' Recap: Don't Surrender to the Index Funds

Index funds are great, Jim Cramer says, but he encourages investors to do some smart stock picking.

Sarepta Therapeutics To Announce Third Quarter 2016 Financial Results And Recent Corporate Developments On October 27, 2016

Sarepta Therapeutics To Announce Third Quarter 2016 Financial Results And Recent Corporate Developments On October 27, 2016

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, will report third quarter 2016 financial results before the NASDAQ Global Market opens...

Trader Be Nimble, Trader Be Quick

Trader Be Nimble, Trader Be Quick

The trading action remains quite tedious, though there are short-term opportunities out there.

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.

Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics

Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics

Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.

Shark Bites: Market Isn't Giving Us Much

You have to dig below the surface and develop a feel for what stocks are leading.

Sarepta (SRPT) Stock Closed Down, Baird: Anthem Policy Doesn't Mean Coverage Denied

Sarepta (SRPT) Stock Closed Down, Baird: Anthem Policy Doesn't Mean Coverage Denied

Although Anthem (ANTM) labeled Sarepta's (SRPT) Duchenne muscular drug as 'not medically necessary,' it doesn't mean the insurer won't offer coverage of the treatment, Baird analysts say.

Sarepta Therapeutics (SRPT) Stock Drops, Anthem Says DMD Drug 'Not Medically Necessary'

Sarepta Therapeutics (SRPT) Stock Drops, Anthem Says DMD Drug 'Not Medically Necessary'

Anthem (ANTM) said today that it doesn't consider Sarepta's (SRPT) Duchenne muscular dystrophy drug to be 'medically necessary,' as it's demonstrated few clinical benefits.

Ignore Market Jitters, Let Price Action Be the Guide

Ignore Market Jitters, Let Price Action Be the Guide

Equities are holding up well, despite concerns that good economic news increases the chances of a rate hike.

Trending Tickers: SDRL, P, SMMT, SRPT

Trending Tickers: SDRL, P, SMMT, SRPT

SeaDrill's chairman and top shareholder seems willing to lend a hand to keep the company's leverage in check.

Sarepta Therapeutics (SRPT) Stock Up on Summit Deal, RBC Bullish

Sarepta Therapeutics (SRPT) Stock Up on Summit Deal, RBC Bullish

Sarepta Therapeutics' (SRPT) multi-country licensing deal with Summit Therapeutics (SMMT) makes the company 'attractive' to potential buyers, RBC says.

Sarepta Therapeutics (SRPT) Stock Gains on Summit Licensing Agreement

Sarepta Therapeutics (SRPT) Stock Gains on Summit Licensing Agreement

Sarepta Therapeutics (SRPT) and Summit Therapeutics (SMMT) signed an exclusive agreement on Tuesday allowing Sarepta to license Summit's DMD drugs in several countries.

Summit Therapeutics Soars on Sarepta Deal

Summit Therapeutics Soars on Sarepta Deal

Summit Therapetuics shares skyrocketed Tuesday on word that it has entered into an exclusive licensing agreement with drugmaker Sarepta Therapeutics.

'Mad Money' Lightning Round: Buy, Buy, Buy Home Depot

'Mad Money' Lightning Round: Buy, Buy, Buy Home Depot

Cramer says Eaton is heading higher and is taking Flex over Brooks Automation.

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Next week brings earnings and more on Deutsche Bank, Cramer says.

Shark Bites: Market Responds With 'Deutsche Who?'

Report of settlement turns the market.

Catabasis Pharmaceuticals And Sarepta Therapeutics Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals And Sarepta Therapeutics Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company ("Catabasis"), and Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces First Patient Dosed In Phase III Clinical Trial Of SRP-4045 And SRP-4053 For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 45 Or 53 Skipping

Sarepta Therapeutics Announces First Patient Dosed In Phase III Clinical Trial Of SRP-4045 And SRP-4053 For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 45 Or 53 Skipping

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne...

Selling Into Strength Can Be a Great Strategic Move

We are seeing lower lows in the indices as I write.

Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys

Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys

Sarepta Therapeutics' (SRPT) stock price target was increased at JMP Securities and RBC Capital on Wednesday due to the potential of Exondys, its Duchenne muscular dystrophy drug.

There's No Debate, Dip Buyers Are Jittery

There's No Debate, Dip Buyers Are Jittery

If the market is looking to correct, election worries are a convenient excuse.